Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Hematologic Malignancy: A Retrospective Study from Central South China
Authors:
- 28 May 2021
- journal article
- research article
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 27 (6) , 800-808
Abstract
Objective: To determine the epidemiology, risk factors, and prognosis of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bloodstream infections (BSIs) among hematology malignancy (HM) patients in China. Method: From January 2010 to June 2018, we retrospectively collected and analyzed the 449 HM patients with E. coli or K. pneumoniae BSIs from three leading hospitals in Hunan Province, China. Results: Two hundred four (45.4%) patients harbored ESBL-producing bacteremia. The proportion of ESBL-producing bacteremia increased significantly with the growth of the year, with a ratio of 34.47% in 2010–2014 to 54.7% in 2015–2018. Comparing with non-ESBL groups in HM patients, central venous catheter (odds ratio [OR] 1.717, p = 0.009), previous antibiotic exposure (OR 1.559, p = 0.035), and E. coli (OR 2.561, p ≤ 0.001) among ESBL groups were independent risk factors. No significant differences in 30-day mortality were tested in patients with BSI caused by ESBL-producing or non-ESBL-producing E. coli and K. pneumoniae (17.1% vs. 16.7%; p = 0. 893). The proportion of carbapenem used within 72 hours after the onset of bacteremia in two groups was high, which was routinely used as “last-resort drugs” in Gram-negative bacterial infections. Risk factors associated with 30-day mortality in HM patients with E. coli or K. pneumoniae bacteremia were myelodysplastic syndrome, incomplete remission of the disease, Multinational Association of Supportive Care in Cancer score 3, catheter insertion, use of vasopressors, and inappropriate antibiotics within 72 hours of BSI onset. Conclusions: The results of this study may provide some references for the whole process management of HM patients with BSIs.Keywords
This publication has 33 references indexed in Scilit:
- Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?F1000Research, 2018
- Prognostic factors and scoring model of hematological malignancies patients with bloodstream infectionsInfection, 2018
- Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospitalLeukemia & Lymphoma, 2015
- Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignanciesInfectious Diseases, 2015
- Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective surveyClinical Microbiology and Infection, 2015
- Antibiotics and Bacterial Resistance in the 21st CenturyPerspectives in Medicinal Chemistry, 2014
- Burden of Bloodstream Infection Caused by Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae Determined Using Multistate Modeling at a Swiss University Hospital and a Nationwide Predictive ModelInfection Control & Hospital Epidemiology, 2013
- Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropeniaEpidemiology and Infection, 2009
- Factors associated with mortality in bacteremic patients with hematologic malignanciesDiagnostic Microbiology and Infectious Disease, 2009
- Risk of bacteraemia and mortality in patients with haematological malignanciesClinical Microbiology and Infection, 2006